Occurrence and Importance of Ether Lipids in Brain

Ether glycerophospholipids are major constituents of neural cell membranes. The overall physicochemical characteristics of ether glycerophospholipids are similar to those of ester-bonded glycerophospholipids except for differences in the phase-transition temperature from gel to liquid crystalline and from lamellar to hexagonal phases. These differences may be responsible for determining physical properties of neural membranes, such as bilayer thickness, area per molecule, side-chain packing, free volume, and lateral domains (Paltauf, 1994; Lohner, 1996). The replacement of one or both acyl ester bonds with an alkenyl or alkyl ether bond produces changes in membrane properties (Lohner, 1996), such as a decrease in membrane dipole potential and alterations in thermotropic phase behavior, ion permeability, and sidechain mobility (Paltauf, 1994). Although the occurrence of ether glycerophospholipid species with inositol or serine as a head group has been reported, the most abundant glycerophospholipid species in brain are those with ethanolamine and choline as head groups. Artificial model membranes composed of ether lipids show markedly different molecular dynamics than membranes consisting of diacyl phospholipids (Lohner, 1996). Studies on model membranes indicate that high ether lipid content provides membranes with an unique microenvironment that is necessary for their optimal function. This includes maintenance of activities of membrane-bound enzymes, regulation of permeability, and optimal function of receptors and ion channels. Perturbation of an ether lipid-rich microenvironment in membranes produces significantly more derangements in membrane dynamics than the perturbation of model membranes composed of diacyl glycerophospholipids. Some neutral lipids also contain ether bonds (Foglia et al., 1988; Bordier et al., 1996). They include 1-O-alkyl-2,3-O-diacylsn- glycerols, 1-O-alk-1' -enyl-2,3-O-diacyl-sn-glycerols, and 1-O-alkyl-2-O-acyl-snglycerols that are analogs of triacylglycerol and diacylglycerols, respectively (Snyder, 1996). These lipids protect against radiation damage and possess antitumor properties. 1-O-alk-1ȧ -enyl-2-O-acyl-sn-glycerols and 1-O-alkyl-2-acyl-sn-glycerols are natural constituents of myocardium. These ether lipids stimulate protein kinase C activity suggesting that ether lipids may play an important role in regulating protein kinase C-mediated cellular differentiation (Ford et al., 1989).


Vinyl Ether Ether Lipid Glyceryl Ether Optic Nerve Hypoplasia Neural Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Acar N., Gregoire S., Andre A., Juaneda P., Joffre C., Bron A. M., Creuzot-Garcher C. P., and Bretillon L. (2007). Plasmalogens in the retina: In situ hybridization of dihydroxyacetone phosphate acyltransferase (DHAP-AT)–the first enzyme involved in their biosynthesis–and comparative study of retinal and retinal pigment epithelial lipid composition. Exp. Eye Res. 84:143–151.PubMedCrossRefGoogle Scholar
  2. André A., Cabaret S., Berdeaux O., Juanéda P., Sébédio J. L., and Chardigny J. M. (2006). Bioequivalence of docosahexaenoic acid and α-linolenic acid supplementations on plasmalogen, long-chain aldehyde, and docosahexaenoic acid levels in the brain of very old rats. Nutr. Res. 26:214–220.CrossRefGoogle Scholar
  3. Blank M. L., Smith Z. L., Cress E. A., and Snyder F. (1994). Molecular species of ethanolamine plasmalogens and transacylase activity in rat tissues are altered by fish oil diets. Biochim. Biophys. Acta Lipids Lipid Metab. 1214:295–302.CrossRefGoogle Scholar
  4. Blank M. L., Smith Z. L., Fitzgerald V., and Snyder F. (1995). The CoA-independent transacylase in PAF biosynthesis: Tissue distribution and molecular species selectivity. Biochim. Biophys. Acta Lipids Lipid Metab. 1254:295–301.CrossRefGoogle Scholar
  5. Bordier C. G., Sellier N., Foucault A. P., and Le Goffic F. (1996). Purification and characterization of deep sea shark Centrophorus squamosus liver oil 1-O-alkylglycerol ether lipids. Lipids 31:521–528.PubMedCrossRefGoogle Scholar
  6. Brinsko S. P., Varner D. D., Love C. C., Blanchard T. L., Day B. C., and Wilson M. E. (2005). Effect of feeding a DHA-enriched nutriceutical on the quality of fresh, cooled and frozen stallion semen. Theriogenology 63:1519–1527.PubMedCrossRefGoogle Scholar
  7. Causeret C. C., Bentejac M. M., Bugaut M. M. (1993). Proteins and enzymes of the peroxisomal membrane in mammals. Biol. Cell 77:89–104.PubMedCrossRefGoogle Scholar
  8. Chatterjee S. and Mayor S. (2001). The GPI-anchor and protein sorting. Cell Mol. Life Sci. 58:1969–1987.PubMedCrossRefGoogle Scholar
  9. Creer M. H. and Gross R. W. (1985). Reversed-phase high-performance liquid chromatographic separation of molecular species of alkyl ether, vinyl ether, and monoacyl lysophospholipids. J. Chromatogr. 338:61–69.PubMedCrossRefGoogle Scholar
  10. Deckelbaum R. J., Worgall T. S., and Seo T. (2006). n-3 Fatty acids and gene expression. Am. J. Clin. Nutr. 83:1520–1525.Google Scholar
  11. Duhm J., Engelmann B., Schönthier U. M., and Streich S. (1993). Accelerated maximal velocity of the red blood cell Na+/K+ pump in hyperlipidemia is related to increase in 1-palmitoyl-2-arachidonoyl-plasmalogen phosphatidylethanolamine. Biochim. Biophys. Acta Biomembr. 1149:185–188.CrossRefGoogle Scholar
  12. Dypbukt J. M., Edman C. C., Sundqvist K., Kakefuda T., Plummer S. M., Harris C. C., and Grafström R. C. (1989). Reactivity of fecapentaene-12 toward thiols, DNA, and these constituents in human fibroblasts. Cancer Res. 49:6058–6063.PubMedGoogle Scholar
  13. Engelmann B. (2004). Plasmalogens: Targets for oxidants and major lipophilic antioxidants. Biochem. Soc. Trans. 32:147–150.PubMedCrossRefGoogle Scholar
  14. Fahy E., Subramaniam S., Brown H. A., Glass C. K., Merrill A. H. J., Murphy R. C., Raetz C. R. H., Russell D. W., Seyama Y., Shaw W., Shimizu T., Spener F., Van Meer G., VanNieuwenhze M. S., White S. H., Witztum J. L., and Dennis E. A. (2005). A comprehensive classification system for lipids. J. Lipid Res. 46:839–861.PubMedCrossRefGoogle Scholar
  15. Farooqui A. A., and Horrocks L. A. (2001). Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist. 7:232–245.PubMedCrossRefGoogle Scholar
  16. Farooqui A. A., and Horrocks L. A. (2004). Plasmalogens, platelet-activating factor, and other ether lipids. In: Nicolaou A. and Kokotos G. (eds.), Bioactive Lipids. Oily Press, Bridgwater, England, pp. 107–134.Google Scholar
  17. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., and Di Marzo V. (2002). Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:294–298.PubMedCrossRefGoogle Scholar
  18. Foglia T. A., Nungesser E., and Marmer W. N. (1988). Oxidation of 1-O-(alk-1-enyl)-2, 3-di-O-acylglycerols: Models for plasmalogen oxidation. Lipids 23:430–434.PubMedCrossRefGoogle Scholar
  19. Ford D. A. and Gross R. W. (1988). Identification of endogenous 1-O-alk-1F-enyl-2-acyl-sn-glycerol in myocardium and its effective utilization by choline phosphotransferase. J. Biol. Chem. 263:2644–2650.PubMedGoogle Scholar
  20. Ford D. A. and Gross R. W. (1989). Differential accumulation of diacyl and plasmalogenic diglycerides during myocardial ischemia. Circ. Res. 64:173–177.PubMedGoogle Scholar
  21. Ford D. A. and Hale C. C. (1996). Plasmalogen and anionic phospholipid dependence of the cardiac sarcolemmal sodium-calcium exchanger. FEBS Lett. 394:99–102.PubMedCrossRefGoogle Scholar
  22. Ford D. A., Miyake R., Glaser P. E., and Gross R. W. (1989). Activation of protein kinase C by naturally occurring ether-linked diglycerides. J. Biol. Chem. 264:13818–13824.PubMedGoogle Scholar
  23. Gills J. J. and Dennis P. A. (2004). The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin. Invest. Drugs. 13:787–797.CrossRefGoogle Scholar
  24. Gills J. J., Holbeck S., Hollingshead M., Hewitt S. M., Kozikowski A. P., and Dennis P. A. (2006). Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt. Mol. Cancer Ther. 5:713–722.PubMedCrossRefGoogle Scholar
  25. Gorgas K., Teigler A., Komljenovic D., and Just W. W. (2006). The ether lipid-deficient mouse: Tracking down plasmalogen functions. Biochim. Biophys. Acta Mol. Cell Res. 1763:1511–1526.CrossRefGoogle Scholar
  26. Guan Z. Z., Grunler J., Piao S. F., and Sindelar P. J. (2001). Separation and quantitation of phospholipids and their ether analogues by high-performance liquid chromatography. Anal. Biochem. 297:137–143.PubMedCrossRefGoogle Scholar
  27. Hahnel D., Huber T., Kurze V., Beyer K., and Engelmann B. (1999). Contribution of copper binding to the inhibition of lipid oxidation by plasmalogen phospholipids. Biochem. J. 340:377–383.PubMedCrossRefGoogle Scholar
  28. Han X. and Gross R. W. (1991). Alterations in membrane dynamics elicited by amphiphilic compounds are augmented in plasmenylcholine bilayers. Biochim. Biophys. Acta Biomembr. 1069:37–45.CrossRefGoogle Scholar
  29. Han X. L. and Gross R. W. (1990). Plasmenylcholine and phosphatidylcholine membrane bilayers possess distinct conformational motifs. Biochemistry 29:4992–4996.PubMedCrossRefGoogle Scholar
  30. Hanuš L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D. E., Kustanovich I., and Mechoulam R. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98:3662–3665.PubMedCrossRefGoogle Scholar
  31. Hayashi H. and Oohashi M. (1995). Incorporation of acetyl-CoA generated from peroxisomal β-oxidation into ethanolamine plasmalogen of rat liver. Biochim. Biophys. Acta Lipids Lipid Metab. 1254:319–325.CrossRefGoogle Scholar
  32. Hayashi H. and Takahata S. (1991). Role of peroxisomal fatty acyl-CoA β-oxidation in phospholipid biosynthesis. Arch. Biochem. Biophys. 284:326–331.PubMedCrossRefGoogle Scholar
  33. Hooper N. M. (1997). Glycosyl-phosphatidylinositol anchored membrane enzymes. Clin. Chim. Acta. 266:3–12.PubMedCrossRefGoogle Scholar
  34. Ishizuka I., Inomata M., Ueno K., and Yamakawa T. (1978). Sulfated glyceroglycolipids in rat brain. Structure sulfation in vivo, and accumulation in whole brain during development. J. Biol. Chem. 253:898–907.PubMedGoogle Scholar
  35. Kim S. Y., Min D. S., Choi J. S., Choi Y. S., Park H. J., Sung K. W., Kim J., and Lee M. Y. (2004). Differential expression of phospholipase D isozymes in the hippocampus following kainic acid-induced seizures. J. Neuropathol. Exp. Neurol. 63:812–820.PubMedGoogle Scholar
  36. Laine K., Jarvinen K., Mechoulam R., Breuer A., and Jarvinen T. (2002). Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci. 43:3216–3222.PubMedGoogle Scholar
  37. Liliom K., Fischer D. J., Virág T., Sun G., Miller D. D., Tseng J. L., Desiderio D. M., Seidel M. C., Erickson J. R., and Tigyi G. (1998a). Identification of a novel growth factor-like lipid, 1-O-cis-alk-1–enyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP) that is present in commercial sphingolipid preparations. J. Biol. Chem. 273:13461–13468.PubMedCrossRefGoogle Scholar
  38. Liliom K., Guan Z., Tseng J. L., Desiderio D. M., Tigyi G., and Watsky M. A. (1998b). Growth factor-like phospholipids generated after corneal injury. Am. J. Physiol. 274:C1065–C1074.PubMedGoogle Scholar
  39. Lohner K. (1996). Is the high propensity of ethanolamine plasmalogens to form non-lamellar lipid structures manifested in the properties of biomembranes? Chem. Phys. Lipids. 81:167–184.PubMedCrossRefGoogle Scholar
  40. Maeba R. and Ueta N. (2004a). A novel antioxidant action of ethanolamine plasmalogens in lowering the oxidizability of membranes. Biochem. Soc. Trans. 32:141–143.PubMedCrossRefGoogle Scholar
  41. Maeba R. and Ueta N. (2004b). Determination of choline and ethanolamine plasmalogens in human plasma by HPLC using radioactive triiodide (1−) ion (125I3 ). Anal. Biochem. 331:169–176.PubMedGoogle Scholar
  42. Maldergem L., Moser A., Vincent M. F., Roland D., Reding R., Otte J. B., Wanders R., and Sokal E. (2005). Orthotopic liver transplantation from a living-related donor in an infant with a peroxisome biogenesis defect of the infantile Refsum disease type. J. Inherited Metab. Dis. 28:593–600.PubMedCrossRefGoogle Scholar
  43. Mechoulam R., Ben Shabat S., Hanuš L., Ligumsky M., Kaminski N. E., Schatz A. R., Gopher A., Almog S., Martin B. R., and Compton D. R. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83–90.PubMedCrossRefGoogle Scholar
  44. Mower H. F., Ichinotsubo D., Wang L. W., Mandel M., Stemmermann G., Nomura A., Heilbrun L., Kamiyama S., and Shimada A. (1982). Fecal mutagens in two Japanese populations with different colon cancer risks. Cancer Res. 42:1164–1169.PubMedGoogle Scholar
  45. Njie Y. F., Kumar A., Qiao Z., Zhong L., and Song Z. H. (2006). Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest Ophthalmol. Vis. Sci. 47:1999–2005.PubMedCrossRefGoogle Scholar
  46. Oka S., Tsuchie A., Tokumura A., Muramatsu M., Suhara Y., Takayama H., Waku K., and Sugiura T. (2003). Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem. 85:1374–1381.PubMedCrossRefGoogle Scholar
  47. Paltauf F. (1994). Ether lipids in biomembranes. Chem. Phys. Lipids. 74:101–139.PubMedCrossRefGoogle Scholar
  48. Pearson R. H. and Pascher I. (1979). The molecular structure of lecithin dihydrate. Nature 281:499–501.PubMedCrossRefGoogle Scholar
  49. Pieringer J., Rao G. S., Mandel P., and Pieringer R. A. (1977). The association of the sulphogalactosylglycerolipid of rat brain with myelination. Biochem. J. 166:421–428.PubMedGoogle Scholar
  50. Plummer S. M., Hall M., and Faux S. P. (1995). Oxidation and genotoxicity of fecapentaene-12 are potentiated by prostaglandin H synthase. Carcinogenesis. 16:1023–1028.PubMedCrossRefGoogle Scholar
  51. Povey A. C., Plummer S. M., Grafstrom R. C., and Harris C. C. (1990). Genotoxic mechanisms of fecapentaene-12 in human cells. Prog. Clin. Biol. Res. 347:155–166.PubMedGoogle Scholar
  52. Reisse S., Rothardt G., Volkl A., and Beier K. (2001). Peroxisomes and ether lipid biosynthesis in rat testis and epididymis. Biol. Reprod. 64:1689–1694.PubMedCrossRefGoogle Scholar
  53. Roberts W. L., Myher J. J., Kuksis A., and Rosenberry T. L. (1988). Alkylacylglycerol molecular species in the glycosylinositol phospholipid membrane anchor of bovine erythrocyte acetylcholinesterase. Biochem. Biophys. Res. Commun. 150:271–277.PubMedCrossRefGoogle Scholar
  54. Rodemer C., Thai T. P., Brugger B., Kaercher T., Werner H., Nave K. A., Wieland F., Gorgas K., and Just W. W. (2003). Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Hum. Mol. Genet. 12:1881–1895.PubMedCrossRefGoogle Scholar
  55. Schulman G., Bodine P. V., and Litwack G. (1992). Modulators of the glucocorticoid receptor also regulate mineralocorticoid receptor function. Biochemistry 31:1734–1741.PubMedCrossRefGoogle Scholar
  56. Seelig J. and Waespe-Sarcevic N. (1978). Molecular order in cis and trans unsaturated phospholipid bilayers. Biochemistry 17:3310–3315.PubMedCrossRefGoogle Scholar
  57. Snyder F. (1995). Platelet-activating factor: The biosynthetic and catabolic enzymes. Biochem. J. 305:689–705.PubMedGoogle Scholar
  58. Snyder F. (1996). Ether-linked lipids and their bioactive species: Occurrence, chemistry, metabolism, regulation, and function. In: Vance D. E. and Vance J. E. (eds.), Biochemistry of Lipids, Lipoproteins and Membranes. Elsevier Science, The Netherlands, pp. 183–209.CrossRefGoogle Scholar
  59. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. (1995). 2-arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:89–97.PubMedCrossRefGoogle Scholar
  60. Sugiura T., Nakane S., Kishimoto S., Waku K., Yoshioka Y., Tokumura A., and Hanahan D. J. (1999). Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1440:194–204.CrossRefGoogle Scholar
  61. Szekely J. and Gates K. S. (2006). Noncovalent DNA binding and the mechanism of oxidative DNA damage by fecapentaene-12. Chem. Res. Toxicol. 19:117–121.PubMedCrossRefGoogle Scholar
  62. Thukkani A. K., Hsu F. F., Crowley J. R., Wysolmerski R. B., Albert C. J., and Ford D. A. (2002). Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens–Production of the chemoattractant, 2-chlorohexadecanal. J. Biol. Chem. 277:3842–3849.PubMedCrossRefGoogle Scholar
  63. Thukkani A. K., McHowat J., Hsu F. F., Brennan M. L., Hazen S. L., and Ford D. A. (2003). Identification of α-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108:3128–3133.PubMedCrossRefGoogle Scholar
  64. Van Tassell R. L., Piccariello T., Kingston D. G., and Wilkins T. D. (1989). The precursors of fecapentaenes: purification and properties of a novel plasmalogen. Lipids 24:454–459.PubMedCrossRefGoogle Scholar
  65. Verhoeven N. M., Roe D. S., Kok R. M., Wanders R. J., Jakobs C., and Roe C. R. (1998). Phytanic acid and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts. J. Lipid Res. 39:66–74.PubMedGoogle Scholar
  66. Visser W. F., van Roermund C. W., IJlst L., Waterham H. R., and Wanders R. J. (2007). Metabolite transport across the peroxisomal membrane. Biochem. J. 401:365–375.PubMedCrossRefGoogle Scholar
  67. Wanders R. J. A. and Waterham H. R. (2006). Peroxisomal disorders: The single peroxisomal enzyme deficiencies. Biochim. Biophys. Acta Mol. Cell Res. 1763:1707–1720.CrossRefGoogle Scholar
  68. Wei H., Kemp S., McGuinness M. C., Moser A. B., and Smith K. D. (2000). Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann. Neurol. 47:286–296.PubMedCrossRefGoogle Scholar
  69. Wildsmith K. R., Albert C. J., Hsu F. F., Kao J. L. F., and Ford D. A. (2006). Myeloperoxidase-derived 2-chlorohexadecanal forms Schiff bases with primary amines of ethanolamine glycerophospholipids and lysine. Chem. Phys. Lipids. 139:157–170.PubMedCrossRefGoogle Scholar
  70. Wolf D. E., Lipscomb A. C., and Maynard V. M. (1988). Causes of nondiffusing lipid in the plasma membrane of mammalian spermatozoa. Biochemistry. 27:860–865.PubMedCrossRefGoogle Scholar
  71. Yachida Y., Kashiwagi M., Mikami T., Tsuchihashi K., Daino T., Akino T., and Gasa S. (1998). Stereochemical structures of synthesized and natural plasmalogalactosylceramides from equine brain. J. Lipid Res. 39:1039–1045.PubMedGoogle Scholar
  72. Yachida Y., Kashiwagi M., Mikami T., Tsuchihashi K., Daino T., Akino T., and Gasa S. (1999). Novel plasmalogalactosylalkylglycerol from equine brain. J. Lipid Res. 40:2271–2278.PubMedGoogle Scholar
  73. Zoeller R. A., Morand O. H., and Raetz C. R. H. (1988). A possible role for plasmalogens in protecting animal cells against photosensitized killing. J. Biol. Chem. 263:11590–11596.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Personalised recommendations